Because MERTK activation by apoptotic lymphoma cells may provide anti-inflammatory and immunosuppressive signals that promote tumor growth, we next tested the requirement for MERTK in an aggressive, preclinical transgenic murine SS lymphoma model, λ-MYC (22), which we have used previously using our derived MycEd1 line (5). The gene discussed is MERTK; the disease is neoplasm.